利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.015 秒)

    KINASE INHIBITORS
    15.
    发明公开
    KINASE INHIBITORS 有权
    激酶抑制剂

    公开(公告)号：EP2493313A1

    公开(公告)日：2012-09-05

    申请号：EP10827573.6

    申请日：2010-10-29

    申请人： Genosco ,  Oscotec Inc.

    发明人： KIM, Hong, Woo ,  KOH, Jong, Sung ,  LEE, Jaekyoo ,  SONG, Ho-Juhn ,  KIM, Youngsam ,  LEE, Hee, Kyu ,  CHOI, Jang-Sik ,  LIM, Sun-Hee ,  CHANG, Sunhwa

    IPC分类号： A01N43/90 ,  A61K31/519

    CPC分类号： A61K31/519 ,  C07D471/04

    摘要： The present invention provides a new group of protein kinase inhibitors, pyrido[4,3,-
    d ]pyrimidin-5-one derivatives, and pharmaceutically acceptable salts thereof that are useful for intreating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrido[4,3,-
    d ]pyrimidin-5-one derivatives.

    摘要翻译： 本发明提供了一组新的蛋白激酶抑制剂，吡啶并[4,3，-d]嘧啶-5-酮衍生物及其药学上可接受的盐，其可用于治疗细胞增殖性疾病和病症如癌症，自身免疫性疾病， 感染，心血管疾病和神经退行性疾病和病症。 本发明提供了合成和施用蛋白激酶抑制剂化合物的方法。 本发明还提供了药物制剂，其包含至少一种蛋白激酶抑制剂化合物以及药学上可接受的载体，稀释剂或赋形剂。 本发明还提供了在合成吡啶并[4,3，-d]嘧啶-5-酮衍生物期间产生的有用中间体。

    KINASE INHIBITORS
    20.
    发明授权
    KINASE INHIBITORS 有权

    公开(公告)号：EP2493313B1

    公开(公告)日：2017-12-13

    申请号：EP10827573.6

    申请日：2010-10-29

    申请人： Genosco ,  Oscotec Inc.

    发明人： KIM, Hong Woo ,  KOH, Jong Sung ,  LEE, Jaekyoo ,  SONG, Ho-Juhn ,  KIM, Youngsam ,  LEE, Hee Kyu ,  CHOI, Jang-Sik ,  LIM, Sun-Hee ,  CHANG, Sunhwa

    IPC分类号： A61K31/519 ,  C07D471/04 ,  A61P35/00 ,  A61P29/00 ,  A61P25/28

    CPC分类号： A61K31/519 ,  C07D471/04

    摘要： The present invention provides a new group of protein kinase inhibitors, pyrido[4,3,-d]pyrimidin-5-one derivatives, and pharmaceutically acceptable salts thereof that are useful for intreating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor. The invention also provides useful intermediates generated during the syntheses of the pyrido[4,3,-d]pyrimidin-5-one derivatives.